| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
|
N Engl J Med
|
2014
|
4.81
|
|
2
|
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
|
J Clin Oncol
|
2007
|
4.29
|
|
3
|
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2009
|
3.48
|
|
4
|
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
|
Oncologist
|
2008
|
2.22
|
|
5
|
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
|
J Clin Oncol
|
2007
|
2.08
|
|
6
|
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
|
J Clin Oncol
|
2008
|
1.99
|
|
7
|
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
|
BMC Cancer
|
2009
|
1.45
|
|
8
|
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2002
|
1.27
|
|
9
|
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.
|
J Clin Oncol
|
2007
|
1.12
|
|
10
|
Anti-HER agents in gastric cancer: from bench to bedside.
|
Nat Rev Gastroenterol Hepatol
|
2011
|
1.08
|
|
11
|
Validity of family history data on primary adult-onset dystonia.
|
Arch Neurol
|
2004
|
1.05
|
|
12
|
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
|
Int J Cancer
|
2014
|
1.02
|
|
13
|
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
|
Angiogenesis
|
2012
|
0.96
|
|
14
|
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
|
BMC Cancer
|
2011
|
0.94
|
|
15
|
Optimal approach to potentially resectable liver metastases from colorectal cancer.
|
Expert Rev Anticancer Ther
|
2008
|
0.88
|
|
16
|
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
|
Target Oncol
|
2013
|
0.88
|
|
17
|
Planning genetic studies on primary adult-onset dystonia: sample size estimates based on examination of first-degree relatives.
|
J Neurol Sci
|
2006
|
0.87
|
|
18
|
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.
|
Future Oncol
|
2014
|
0.84
|
|
19
|
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
|
Clin Colorectal Cancer
|
2013
|
0.83
|
|
20
|
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
|
Br J Clin Pharmacol
|
2008
|
0.82
|
|
21
|
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
|
Tumori
|
2015
|
0.82
|
|
22
|
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
|
Pharmacogenomics
|
2008
|
0.81
|
|
23
|
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer.
|
Tumori
|
2006
|
0.81
|
|
24
|
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
|
Crit Rev Oncol Hematol
|
2010
|
0.81
|
|
25
|
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
|
Oncology
|
2012
|
0.81
|
|
26
|
Motoneuron disease after electric injury: a case report.
|
Neurol Sci
|
2008
|
0.81
|
|
27
|
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
|
Clin Colorectal Cancer
|
2011
|
0.80
|
|
28
|
Palliative treatment of unresectable metastatic colorectal cancer.
|
Expert Opin Pharmacother
|
2010
|
0.80
|
|
29
|
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
|
Cancer Chemother Pharmacol
|
2006
|
0.80
|
|
30
|
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.
|
Int J Biol Markers
|
2015
|
0.80
|
|
31
|
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
|
Cancer Chemother Pharmacol
|
2010
|
0.79
|
|
32
|
Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?
|
J Clin Oncol
|
2011
|
0.78
|
|
33
|
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target.
|
Anal Quant Cytol Histol
|
2009
|
0.78
|
|
34
|
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
|
Curr Cancer Drug Targets
|
2010
|
0.78
|
|
35
|
Sensitivity and specificity of a self-administered questionnaire for familial screening of adult-onset dystonia.
|
Mov Disord
|
2006
|
0.78
|
|
36
|
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment.
|
Cancer Biol Ther
|
2013
|
0.76
|
|
37
|
Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence.
|
Medicine (Baltimore)
|
2015
|
0.76
|
|
38
|
Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
|
Oncology
|
2014
|
0.76
|
|
39
|
Menopause and menarche in patients with primary blepharospasm: an exploratory case-control study.
|
Eur Neurol
|
2002
|
0.75
|
|
40
|
5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.
|
Am J Clin Oncol
|
2004
|
0.75
|
|
41
|
Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter.
|
Clin Cancer Res
|
2012
|
0.75
|
|
42
|
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.
|
Expert Opin Biol Ther
|
2011
|
0.75
|
|
43
|
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
|
Oncology
|
2016
|
0.75
|
|
44
|
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
|
Curr Opin Oncol
|
2008
|
0.75
|